Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Sonoma Pharmaceuticals Inc
Total Equity
Sonoma Pharmaceuticals Inc
Total Equity Peer Comparison
Competitive Total Equity Analysis
Latest Figures & CAGR of Competitors
Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
|
Total Equity
$6.7m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
7%
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Equity
$70B
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-1%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Equity
$16.5B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
2%
|
CAGR 10-Years
1%
|
|
Pfizer Inc
NYSE:PFE
|
Total Equity
$89B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
1%
|
|
Merck & Co Inc
NYSE:MRK
|
Total Equity
$40.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-2%
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Equity
$12.8B
|
CAGR 3-Years
23%
|
CAGR 5-Years
39%
|
CAGR 10-Years
-4%
|
See Also
What is Sonoma Pharmaceuticals Inc's Total Equity?
Total Equity
6.7m
USD
Based on the financial report for Dec 31, 2023, Sonoma Pharmaceuticals Inc's Total Equity amounts to 6.7m USD.
What is Sonoma Pharmaceuticals Inc's Total Equity growth rate?
Total Equity CAGR 10Y
7%
Over the last year, the Total Equity growth was 20%. The average annual Total Equity growth rates for Sonoma Pharmaceuticals Inc have been -18% over the past three years , -13% over the past five years , and 7% over the past ten years .